Press Room

51st Organic Process Research and Development (OPR&D)

Start
Tuesday, March 12, 2024
End
Thursday, March 14, 2024
Location: San Diego, USA

Visit Hovione at OPR&D, the Leading Process Chemistry Conference from 12-14 March in San Diego, USA. 

The chemical and pharma industries are fast moving and ever changing and the efficient conversion of a chemical process into a process for manufacture on tonnage scale has always been of importance. However, in the current economic and regulatory climate, it has become increasingly vital and challenging to do so efficiently and sustainably. The conference is the place to be to learn about the latest scientific updates in the industry and to network with chemical experts from around the globe.

Schedule a meeting with our experts to learn more about our custom development and manufacturing of APIs. With worldwide locations, an exemplary regulatory track record and a ‘can do’ approach, our experienced development and manufacturing teams will provide the competence, capacity, safety and quality you expect to manufacture your product on time, on budget and to the very highest standards.

 

schedule a meeting

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026